The DOI matches its Crossref record; 81 of the 81 references it cites were found in a registry or an index.
Towards effective COVID‑19 vaccines: Updates, perspectives and challenges (Review)
Open accessAbstract
In the current context of the pandemic triggered by SARS-COV-2, the immunization of the population through vaccination is recognized as a public health priority. In the case of SARS‑COV‑2, the genetic sequencing was done quickly, in one month. Since then, worldwide research has focused on obtaining a vaccine. This has a major economic impact because new technological platforms and advanced genetic engineering procedures are required to obtain a COVID‑19 vaccine. The most difficult scientific challenge for this future vaccine obtained in the laboratory is the proof of clinical safety and efficacy. The biggest challenge of manufacturing is the construction and validation of production platforms capable of making the vaccine on a large scale.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N.-H., Nitsche, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.02.052 · Cited by 20,286
mRNA vaccines — a new era in vaccinology
Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.243 · Cited by 4,667 · cited 1×
“The technique transforms the human body into a ‘living laboratory’, because the whole process is no longer carried out in the laboratory, but directly in the body that received the vaccine (65).”
MethodCoronaviruses: An Overview of Their Replication and Pathogenesis
Fehr, A. R., & Perlman, S. (2015) · Methods in Molecular Biology · doi:10.1007/978-1-4939-2438-7_1 · Cited by 3,787
Emerging coronaviruses: Genome structure, replication, and pathogenesis
Chen, Y., Liu, Q., & Guo, D. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25681 · Cited by 3,062
Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2
Wang, Q., Zhang, Y., Wu, L., Niu, S., Song, C., Zhang, Z., Lu, G., Qiao, C., Hu, Y., Yuen, K.-Y., et al. (2020) · Cell · doi:10.1016/j.cell.2020.03.045 · Cited by 2,892 · cited 1×
“In the case of SARS-cOV-2, the receptor is the angiotensin converting enzyme 2 (AcE2), which is found in large quantities in the respiratory tract and lung parenchyma (51-54).”
BackgroundThe COVID-19 vaccine development landscape
Thanh Le, T., Andreadakis, Z., Kumar, A., Gómez Román, R., Tollefsen, S., Saville, M., & Mayhew, S. (2020) · Nature Reviews Drug Discovery · doi:10.1038/d41573-020-00073-5 · Cited by 1,954
Coronaviruses post-SARS: update on replication and pathogenesis
Perlman, S., & Netland, J. (2009) · Nature Reviews Microbiology · doi:10.1038/nrmicro2147 · Cited by 1,764
Red Book: 2024–2027 Report of the Committee on Infectious Diseases
Committee on Infectious Diseases, A. A. O. P. (2024) · doi:10.1542/9781610027359 · Cited by 1,548
Lukassen, S., Chua, R. L., Trefzer, T., Kahn, N. C., Schneider, M. A., Muley, T., Winter, H., Meister, M., Veith, C., Boots, A. W., et al. (2020) · The EMBO Journal · doi:10.15252/embj.20105114 · Cited by 1,100
Fogel, D. B. (2018) · Contemporary Clinical Trials Communications · doi:10.1016/j.conctc.2018.08.001 · Cited by 1,035
Genotype and phenotype of COVID-19: Their roles in pathogenesis
Mousavizadeh, L., & Ghasemi, S. (2021) · Journal of Microbiology, Immunology and Infection · doi:10.1016/j.jmii.2020.03.022 · Cited by 962
Coronavirus Genomics and Bioinformatics Analysis
Woo, P. C. Y., Huang, Y., Lau, S. K. P., & Yuen, K.-Y. (2010) · Viruses · doi:10.3390/v2081803 · Cited by 913
Leung, J. M., Yang, C. X., Tam, A., Shaipanich, T., Hackett, T.-L., Singhera, G. K., Dorscheid, D. R., & Sin, D. D. (2020) · European Respiratory Journal · doi:10.1183/13993003.00688-2020 · Cited by 845
COVID-19: what has been learned and to be learned about the novel coronavirus disease
Yi, Y., Lagniton, P. N. P., Ye, S., Li, E., & Xu, R.-H. (2020) · International Journal of Biological Sciences · doi:10.7150/ijbs.45134 · Cited by 832
Structural Basis for RNA Replication by the SARS-CoV-2 Polymerase
Wang, Q., Wu, J., Wang, H., Gao, Y., Liu, Q., Mu, A., Ji, W., Yan, L., Zhu, Y., Zhu, C., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.034 · Cited by 776
SARS-CoV-2 and COVID-19: The most important research questions
Yuen, K.-S., Ye, Z. W., Fung, S.-Y., Chan, C.-P., & Jin, D.-Y. (2020) · Cell & Bioscience · doi:10.1186/s13578-020-00404-4 · Cited by 707
Advances in mRNA Vaccines for Infectious Diseases
Zhang, C., Maruggi, G., Shan, H., & Li, J. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00594 · Cited by 665
Developing mRNA-vaccine technologies
Schlake, T., Thess, A., Fotin-Mleczek, M., & Kallen, K.-J. (2012) · RNA Biology · doi:10.4161/rna.22269 · Cited by 622
mRNA as a Transformative Technology for Vaccine Development to Control Infectious Diseases
Maruggi, G., Zhang, C., Li, J., Ulmer, J. B., & Yu, D. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.01.020 · Cited by 507
The promise of mRNA vaccines: a biotech and industrial perspective
Jackson, N. A. C., Kester, K. E., Casimiro, D., Gurunathan, S., & DeRosa, F. (2020) · npj Vaccines · doi:10.1038/s41541-020-0159-8 · Cited by 498 · cited 2×
“The mRNA (encoding RiboNucleic Acid) vaccine encodes a stable prefused form (the form before being fused to the cell membrane of the host cell) of Spike protein (S) (63).”
BackgroundThe Immunopathogenesis of Sepsis in Elderly Patients
Opal, S. M., Girard, T. D., & Ely, E. W. (2005) · Clinical Infectious Diseases · doi:10.1086/432007 · Cited by 460
Mazur, N. I., Higgins, D., Nunes, M. C., Melero, J. A., Langedijk, A. C., Horsley, N., Buchholz, U. J., Openshaw, P. J., McLellan, J. S., Englund, J. A., et al. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(18)30292-5 · Cited by 457
DNA Vaccines—How Far From Clinical Use?
Hobernik, D., & Bros, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113605 · Cited by 457
COVID-19: a new challenge for human beings
Yang, P., & Wang, X. (2020) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-0407-x · Cited by 452
Zinc and respiratory tract infections: Perspectives for COVID‑19 (Review)
Skalny, A., Rink, L., Ajsuvakova, O., Aschner, M., Gritsenko, V., Alekseenko, S., Svistunov, A., Petrakis, D., Spandidos, D., Aaseth, J., et al. (2020) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2020.4575 · Cited by 435
Self-citationIs COVID-19 receiving ADE from other coronaviruses?
Tetro, J. A. (2020) · Microbes and Infection · doi:10.1016/j.micinf.2020.02.006 · Cited by 434
Innate Immune Evasion by Human Respiratory RNA Viruses
Kikkert, M. (2020) · Journal of Innate Immunity · doi:10.1159/000503030 · Cited by 406
DNA and RNA-based vaccines: principles, progress and prospects
Leitner, W. W., Ying, H., & Restifo, N. P. (1999) · Vaccine · doi:10.1016/s0264-410x(99)00271-6 · Cited by 402
Use of rodents as models of human diseases
Vandamme, T. (2014) · Journal of Pharmacy And Bioallied Sciences · doi:10.4103/0975-7406.124301 · Cited by 389
Immunosenescence in aging: Between immune cells depletion and cytokines up-regulation
Ventura, M. T., Casciaro, M., Gangemi, S., & Buquicchio, R. (2017) · Clinical and Molecular Allergy · doi:10.1186/s12948-017-0077-0 · Cited by 389
Clinical Applications of DNA Vaccines: Current Progress
Ferraro, B., Morrow, M. P., Hutnick, N. A., Shin, T. H., Lucke, C. E., & Weiner, D. B. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir334 · Cited by 381
Physiological and pathological regulation of ACE2, the SARS-CoV-2 receptor
Li, Y., Zhou, W., Yang, L., & You, R. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104833 · Cited by 378
Molecular mechanisms for enhanced DNA vaccine immunogenicity
Li, L., & Petrovsky, N. (2016) · Expert Review of Vaccines · doi:10.1586/14760584.2016.1124762 · Cited by 335
Rationalizing the development of live attenuated virus vaccines
Lauring, A. S., Jones, J. O., & Andino, R. (2010) · Nature Biotechnology · doi:10.1038/nbt.1635 · Cited by 328
Franceschi, C., Salvioli, S., Garagnani, P., de Eguileor, M., Monti, D., & Capri, M. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00982 · Cited by 290
Liu, W., Fontanet, A., Zhang, P., Zhan, L., Xin, Z., Baril, L., Tang, F., Lv, H., & Cao, W. (2006) · The Journal of Infectious Diseases · doi:10.1086/500469 · Cited by 285
Perspectives on therapeutic neutralizing antibodies against the Novel Coronavirus SARS-CoV-2
Zhou, G., & Zhao, Q. (2020) · International Journal of Biological Sciences · doi:10.7150/ijbs.45123 · Cited by 266
Risk in vaccine research and development quantified
Pronker, E. S., Weenen, T. C., Commandeur, H., Claassen, E. H. J. H. M., & Osterhaus, A. D. M. E. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057755 · Cited by 253
Engin, A. B., Nikitovic, D., Neagu, M., Henrich-Noack, P., Docea, A. O., Shtilman, M. I., Golokhvast, K., & Tsatsakis, A. M. (2017) · Particle and Fibre Toxicology · doi:10.1186/s12989-017-0199-z · Cited by 246
Self-citationEditorial: Nicotine and SARS-CoV-2: COVID-19 may be a disease of the nicotinic cholinergic system
Farsalinos, K., Niaura, R., Le Houezec, J., Barbouni, A., Tsatsakis, A., Kouretas, D., Vantarakis, A., & Poulas, K. (2020) · Toxicology Reports · doi:10.1016/j.toxrep.2020.04.012 · Cited by 245
Self-citationA new threat from an old enemy: Re‑emergence of coronavirus (Review)
Docea, A., Tsatsakis, A., Albulescu, D., Cristea, O., Zlatian, O., Vinceti, M., Moschos, S., Tsoukalas, D., Goumenou, M., Drakoulis, N., et al. (2020) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2020.4555 · Cited by 218
Self-citationReduced tetanus antibody titers in overweight children
Eliakim, A., Swindt, C., Zaldivar, F., Casali, P., & Cooper, D. M. (2006) · Autoimmunity · doi:10.1080/08916930600597326 · Cited by 209
Influenza Vaccination Strategies: Comparing Inactivated and Live Attenuated Influenza Vaccines
Sridhar, S., Brokstad, K., & Cox, R. (2015) · Vaccines · doi:10.3390/vaccines3020373 · Cited by 209
Contamination of Poliovirus Vaccines With Simian Virus 40 (1955-1963) and Subsequent Cancer Rates
Strickler, H. D. (1998) · JAMA · doi:10.1001/jama.279.4.292 · Cited by 192
Primary vaccine failure to routine vaccines: Why and what to do?
Wiedermann, U., Garner‐Spitzer, E., & Wagner, A. (2016) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2015.1093263 · Cited by 176
Boda, D., Docea, A., Calina, D., Ilie, M., Caruntu, C., Zurac, S., Neagu, M., Constantin, C., Branisteanu, D., Voiculescu, V., et al. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4256 · Cited by 176
Self-citationThe effect of aging of the immune system on vaccination responses
Lord, J. M. (2013) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.24696 · Cited by 175
The introduction of new vaccines into developing countries
Mahoney, R. T., & Maynard, J. E. (1999) · Vaccine · doi:10.1016/s0264-410x(98)00246-1 · Cited by 161
Increased expression of CD8 marker on T-cells in COVID-19 patients
Ganji, A., Farahani, I. K., Khansarinejad, B., Ghazavi, A., & Mosayebi, G. (2020) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2020.102437 · Cited by 160
Landscape Analysis of Interactions between Nutrition and Vaccine Responses in Children
Savy, M., Edmond, K. M., Fine, P., Hall, A., Hennig, B. J., Moore, S. E., Mulholland, K., Schaible, U. E., & Prentice, A. M. (2009) · Journal of Nutrition · doi:10.3945/jn.109.105312 · Cited by 159
Escherichia coli-derived virus-like particles in vaccine development
Huang, X., Wang, X., Zhang, J., Xia, N., & Zhao, Q. (2017) · npj Vaccines · doi:10.1038/s41541-017-0006-8 · Cited by 156
Avoiding pitfalls in the pursuit of a COVID-19 vaccine
Peeples, L. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2005456117 · Cited by 152 · cited 1×
“When such adverse effects are identified, delays in the production process inevitably occur (41).”
BackgroundΓούμενου, Μ., Sarigiannis, D. A., Tsatsakis, A. M., Anesti, O., Docea, A. O., Petrakis, D., Tsoukalas, D., Kostoff, R. N., Rakitskii, V., Spandidos, D. A., et al. (2020) · Molecular Medicine Reports · doi:10.3892/mmr.2020.11079 · Cited by 139
Self-citationDocea, A. O., Gofiţă, E., Γούμενου, Μ., Călina, D. C., Rogoveanu, O. C., Văruț, M. C., Olaru, C., Kerasioti, E., Fountoucidou, P., Taitzoglou, I., et al. (2018) · Food and Chemical Toxicology · doi:10.1016/j.fct.2018.03.052 · Cited by 136
Self-citationTsatsakis, A. M., Petrakis, D., Νikolouzakis, Τ. Κ., Docea, A. O., Călina, D. C., Vinceti, M., Γούμενου, Μ., Kostoff, R. N., Mamoulakis, C., Aschner, M., et al. (2020) · Food and Chemical Toxicology · doi:10.1016/j.fct.2020.111418 · Cited by 136
Self-citationViral-Induced Enhanced Disease Illness
Smatti, M. K., Thani, A. A. A., & Yassine, H. M. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.02991 · Cited by 128
Han, S. (2015) · Clinical and Experimental Vaccine Research · doi:10.7774/cevr.2015.4.1.46 · Cited by 115
Viral vectors for vaccine applications
Choi, Y., & Chang, J. (2013) · Clinical and Experimental Vaccine Research · doi:10.7774/cevr.2013.2.2.97 · Cited by 112
Mendoza, Y. G., Garric, E., Leach, A. J., Lievens, M., Ofori‐Anyinam, O., Pirçon, J., Stegmann, J., Vandoolaeghe, P., Otieno, L., Otieno, W., et al. (2019) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2019.1586040 · Cited by 103
Recent advances in the production of recombinant subunit vaccines inPichia pastoris
Wang, M., Jiang, S., & Wang, Y. (2016) · Bioengineered · doi:10.1080/21655979.2016.1191707 · Cited by 99
Reid, N., Moritz, K. M., & Akison, L. K. (2019) · Pediatric Allergy and Immunology · doi:10.1111/pai.13099 · Cited by 88
Antibodies and vaccines against Middle East respiratory syndrome coronavirus
Xu, J., Jia, W., Wang, P., Zhang, S., Shi, X., Wang, X., & Zhang, L. (2019) · Emerging Microbes & Infections · doi:10.1080/22221751.2019.1624482 · Cited by 88
Tsatsakis, A. M., Docea, A. O., Constantin, C., Călina, D. C., Zlatian, O. M., Νikolouzakis, Τ. Κ., Stivaktakis, P. D., Kalogeraki, A. M., Liesivuori, J., Tzanakakis, G. N., et al. (2019) · Toxicology Letters · doi:10.1016/j.toxlet.2019.09.004 · Cited by 88
Self-citationPrincipal Controversies in Vaccine Safety in the United States
DeStefano, F., Bodenstab, H. M., & Offit, P. A. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz135 · Cited by 86
Association of nutraceutical supplements with longer telomere length
Tsoukalas, D., Fragkiadaki, P., Docea, A. O., Alegakis, A. K., Sarandi, E., Vakonaki, E., Salataj, E., Kouvidi, E., Nikitovic, D., Kovatsi, L., et al. (2019) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2019.4191 · Cited by 86
Self-citationDocea, A. O., Γούμενου, Μ., Călina, D. C., Arsene, A. L., Drăgoi, C. M., Gofiţă, E., Pisoschi, C. G., Zlatian, O. M., Stivaktakis, P. D., Νikolouzakis, Τ. Κ., et al. (2019) · Toxicology Letters · doi:10.1016/j.toxlet.2019.04.005 · Cited by 85
Self-citationFountoucidou, P., Veskoukis, A. S., Kerasioti, E., Docea, A. O., Taitzoglou, I., Liesivuori, J., Tsatsakis, A. M., & Kouretas, D. (2019) · Toxicology Letters · doi:10.1016/j.toxlet.2019.09.015 · Cited by 77
Self-citationVaccination in patients with immunosuppression
Arvas, A. (2014) · Türk Pediatri Arşivi · doi:10.5152/tpa.2014.2206 · Cited by 73
Γούμενου, Μ., Spandidos, D. A., & Tsatsakis, A. M. (2020) · Molecular Medicine Reports · doi:10.3892/mmr.2020.11037 · Cited by 69
Self-citationAnalysis of porcine circovirus type 1 detected in Rotarix vaccine
Baylis, S. A., Finsterbusch, T., Bannert, N., Blümel, J., & Mankertz, A. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.11.028 · Cited by 65
Receptor-binding domain-based subunit vaccines against MERS-CoV
Zhang, N., Tang, J., Lu, L., Jiang, S., & Du, L. (2014) · Virus Research · doi:10.1016/j.virusres.2014.11.013 · Cited by 61
Stawicki, S. P., Wojda, T., Valenza, P., Cornejo, K. M., McGinley, T. C., Galwankar, S., Kelkar, D. S., Sharpe, R., & Papadimos, T. J. (2015) · Journal of Global Infectious Diseases · doi:10.4103/0974-777x.170495 · Cited by 53
Messenger RNA‐based vaccines: progress, challenges, applications
Kramps, T., & Probst, J. (2013) · WIREs RNA · doi:10.1002/wrna.1189 · Cited by 50
Dang‐Tan, T., Mahmud, S. M., Puntoni, R., & Franco, E. L. (2004) · Oncogene · doi:10.1038/sj.onc.1207877 · Cited by 49
Wouters-Wesseling, W., Rozendaal, M. J., Snijder, M. B., Graus, Y., Rimmelzwaan, G. F., de Groot, C. P. G. M., & BINDELS, J. G. (2002) · The Journals of Gerontology Series A · doi:10.1093/gerona/57.9.m563 · Cited by 46
Keusch, G. T. (1991) · Clinical Infectious Diseases · doi:10.1093/clinids/13.supplement_6.s486 · Cited by 37
Hashem, M. M., Abo‐EL‐Sooud, K., Abd‐Elhakim, Y. M., Badr, Y. A.-H., El‐Metwally, A. E., & Bahy-EL-Dien, A. (2020) · Journal of Trace Elements in Medicine and Biology · doi:10.1016/j.jtemb.2020.126473 · Cited by 35
First-in-human clinical trials with vaccines—what regulators want
Goetz, K., Pfleiderer, M., & Schneider, C. K. (2010) · Nature Biotechnology · doi:10.1038/nbt0910-910 · Cited by 31
ImmunIty for tHe PeoPle: The CHallenge of aCHIevIng HIgH vaCCIne Coverage in amerICan HIstory
Colgrove, J. K. (2007) · Public Health Reports · doi:10.1177/003335490712200215 · Cited by 29
Delfosse, V. C., Tasat, D. R., & Gioffré, A. (2013) · Environmental Toxicology · doi:10.1002/tox.21936 · Cited by 9
Omran, G. A. (2019) · Immunopharmacology and Immunotoxicology · doi:10.1080/08923973.2018.1533967 · Cited by 7
Cited by
COVID-19 Vaccine Hesitancy Worldwide: A Concise Systematic Review of Vaccine Acceptance Rates
Sallam, M. (2021) · Vaccines · doi:10.3390/vaccines9020160 · Cited by 2,128
COVID-19 vaccine challenges: What have we learned so far and what remains to be done?
Forman, R., Shah, S., Jeurissen, P., Jit, M., & Mossialos, E. (2021) · Health Policy · doi:10.1016/j.healthpol.2021.03.013 · Cited by 307
DNA vaccines against COVID-19: Perspectives and challenges
Silveira, M. M., Moreira, G. M. S. G., & Mendonça, M. (2021) · Life Sciences · doi:10.1016/j.lfs.2020.118919 · Cited by 285
Acute surgical abdomen during the COVID 19 pandemic: Clinical and therapeutic challenges
Serban, D., Socea, B., Badiu, C., Tudor, C., Balasescu, S., Dumitrescu, D., Trotea, A., Spataru, R., Vancea, G., Dascalu, A., et al. (2021) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2021.9950 · Cited by 39
Metadata
- Authors
- Calina, D., Docea, A., Petrakis, D., Egorov, A., Ishmukhametov, A., Gabibov, A., Shtilman, M., Kostoff, R., Carvalho, F., Vinceti, M., Spandidos, D., & Tsatsakis, A.
- Venue
- International Journal of Molecular Medicine
- Publisher
- Spandidos Publications
- Published
- 2020-05-06
- Volume
- 46
- Issue
- 1
- Pages
- 3-16
- ISSN
- 1107-3756 (ISSN-L)
- 1791-244X
- OpenAlex
- W3021502717
- Cited by
- 318
- References
- 81
- FWCI
- 8.81
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.